Recent Blog Posts

View Post: Rituximab effective for eye complications of Graves' disease at ...
14 Nov 2009 by Doctor Z  
The NIH-funded study suggests that rituximab is a potentially effective new treatment for the most severe forms of Graves' eye disease. “These patients had already received the maximum level of steroid treatment,” says Douglas. ...
View Blog: iHealthBulletin News - http://ihealthbulletin.com/blog/

---

View Post: Irish Medical Times
News
Irish Medicines Board gives safety ... ...
View Blog: The Irish Medicines Board (IMB) has drawn doctors' attention to an important safety warning relating to rituximab (MabThera) and Progressive Multifocal Leukoencephalopathy (PML) in patients treated for rheumatoid arthritis (RA).

---

View Post: Rituximab treatment in rheumatoid arthritis: how does it work?
25 Nov 2009 by Zamp  
Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of ...
View Blog: Bio Topics - http://biotopics.zampbioworld.org/

---

View Post: Anabolic Steroids Blog - iSteroids . com » Rituximab is safe and ...
17 Nov 2009 by i steroids  
Rituximab is safe and effective for treating rheumatoid arthritis As per the biggest study of its kind, rituximab that is used to treat rheumatoid arthritis (RA) is safe and effective at the same time. The results of this study were ...
View Blog: Anabolic Steroids Blog - iSteroids . com - http://www.isteroids.com/blog/

---

View Post: Blood -- Rituximab inhibits B-cell receptor signaling
17 Nov 2009 by Kheirallah, S., Caron, P., Gross, E., Quillet-M...  
Rituximab (RTX), a monoclonal antibody directed against the CD20 protein, is a drug commonly used in the treatment of B cell derived lymphoid neoplasias and of antibody-mediated auto-immune diseases. ...
View Blog: BLOOD First Edition Papers - http://bloodjournal.hematologylibrary.org/

---

View Post: Type 1 Diabetes May Have a New Foe
25 Nov 2009
In this phase 2 trial, 87 patients with newly diagnosed type 1 diabetes were randomly assigned to receive rituximab infusions or a placebo at one-week intervals for four weeks. After one year, C-peptide levels -- an indicator of how ...
View Blog: Health, Fitness, Wellness News at VitaBeat - http://www.vitabeat.com/

---

View Post: NICE issues ACD on rituximab for relapsed chronic lymphocytic ...
10 Nov 2009
Rituximab in combination with fludarabine and cyclophosphamide is recommended as an option for the treatment of relapsed or refractory chronic lymphocytic leukaemia except when the condition is refractory to fludarabine (i.e. not ...
View Blog: NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/

---

View Post: Rituximab hit with FDA complete response letter for leukaemia
19 Nov 2009
The US FDA has issued a complete response letter to Genentech and Biogen Idec for the companies' applications for Rituxan/MabThera (rituximab) for patients with previously untreated and previously treated chronic lymphocytic leukaemia ...
View Blog: Scrip News - Home - RSS - http://www.scripnews.com/home/

---